NEPTUNUS: HW130 injection completed Phase I clinical trial
NEPTUNUS announced that its wholly-owned subsidiary has completed Phase I clinical trials for the HW130 injection and obtained the Phase I clinical research report. HW130 is a novel anti-tumor drug with independent intellectual property rights, and has received clinical trial approval from the National Medical Products Administration and the U.S. FDA. The drug has shown good safety and tolerability in patients with advanced malignant solid tumors, providing a basis for subsequent clinical trials
According to the Zhitong Finance APP, NEPTUNUS (000078.SZ) announced that its wholly-owned subsidiary Shenzhen NEPTUNUS Pharmaceutical Technology Research Institute Co., Ltd. (referred to as "NEPTUNUS Pharmaceutical Research Institute") has recently completed Phase I clinical trials for the HW130 injection and obtained the Phase I clinical research report.
HW130 injection is a new anti-tumor drug independently developed by the NEPTUNUS Pharmaceutical Research Institute, with independent intellectual property rights, and has received clinical trial approvals from the National Medical Products Administration and the U.S. FDA. It has tumor vascular blocking effects and reduces severe adverse reactions from tumor chemotherapy while enhancing the sensitivity to chemotherapy, improving the clinical efficacy of comprehensive tumor treatment; it causes minimal damage to normal organ tissues and has high targeting ability. The development of this project can address unmet clinical needs to some extent and has significant development potential and market space.
This clinical trial is an open-label, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of HW130 in patients with advanced malignant solid tumors, divided into two parts: single-dose tolerability observation and multiple-dose tolerability observation. This clinical study completed the assessment of the maximum tolerated dose in humans and pharmacokinetic analysis. The results indicate that HW130 injection has good safety and tolerability, with no adverse events related to the study drug leading to permanent discontinuation or early withdrawal from the trial, and no adverse events resulting in death. The Phase I clinical trial of HW130 injection achieved its expected objectives, providing sufficient basis for subsequent clinical trial exploration
